No risk, no reward—that’s the concept driving the startups and entrepreneurs scheduled to present at next week’s 12th Annual BIO Investor Forum as a part of the newly-announced National Science Foundation (NSF) track of presenting companies. Expanding on the success of the Discovery Track Presentations, the 2013 BIO Investor Forum will feature a dedicated track of 10 NSF-funded companies focused on drug discovery, diagnostics and other related technologies.
The companies are supported by the NSF Small Business Innovation Research (SBIR) program, which incentivizes and enables early-stage biotech companies to undertake R&D on transformational technologies with significant societal or commercial impact. For example:
Jade Therapeutics develops locally administered, sustained release therapeutics that improve corneal healing following damage from disease or injury.
Parabon Nanolabs is a DNA technology company that develops therapeutic and forensic products made possible by recent advances in DNA sequencing, processing and manufacturing technologies.
Nano3D Biosciences develops a device for culturing cells in three-dimensions by magnetic levitation.
A full list of NSF-track presentations is available here. Each of the companies has been rigorously vetted through the NSF review process, and a majority of the presenting companies have received SBIR Phase II grants, which provide $750,000 over two years.
For early-stage investors, the NSF track presents a valuable opportunity to form long-term partnerships that will help bring these innovative technologies to market. We hope you’ll join us next week Oct 8-9 at the Palace Hotel in San Francisco to learn more about these companies and more than 100 others scheduled to present at BIO Investor Forum.